Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Beth O. Van Emburgh(IFOM), Alberto Bardelli(Candiolo Cancer Institute)
Cited by 211
Related Papers
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
|Nature Communications|2015|305
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
|Nature Medicine|2022|251
Exploiting <scp>DNA</scp> repair defects in colorectal cancer
|Molecular Oncology|2019|134
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
|Nature Communications|2015|128
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
|Clinical Cancer Research|2014|114